Microbot Medical Aligns LIBERTY System with New AMA Radiation Protection Policy
MBOT sits 89% above its 52-week low of $1.25.
Summary
Microbot Medical announced its LIBERTY Endovascular Robotic System aligns with the AMA's new policy to protect healthcare professionals from ionizing radiation, reinforcing the product's safety benefits ahead of its full market release.
Key Events · Product Development and Regulatory · MBOT
-
AMA Adopts New Radiation Protection Policy
The American Medical Association (AMA) adopted a new policy in late 2025 to strengthen protections for healthcare professionals and trainees from ionizing radiation, emphasizing research, PPE effectiveness, and education.
-
LIBERTY System Addresses Radiation Concerns
Microbot Medical's LIBERTY Endovascular Robotic System, which allows remote operation, demonstrated a 92% relative reduction in radiation exposure in the ACCESS-PVI Study, directly addressing the AMA's new policy.
-
Strategic Market Positioning
The company believes this AMA guidance creates meaningful opportunities for LIBERTY, especially given concerns about long-term health effects of radiation and staffing shortages in endovascular specialties.
-
Commercialization Update
Microbot Medical commenced a Limited Market Release of LIBERTY in late 2025 and plans a Full Market Release at the Society of Interventional Radiology (SIR) conference in April 2026.
Analysis · MBOT · Industrial Applications And Services
Microbot Medical is strategically positioning its LIBERTY Endovascular Robotic System by highlighting its alignment with the American Medical Association's (AMA) recently adopted policy to protect healthcare professionals from ionizing radiation. This announcement reinforces the value proposition of LIBERTY, which demonstrated a 92% reduction in radiation exposure in a study, by connecting it to a significant industry concern and a major medical association's guidance. While not a direct revenue event, this strengthens the company's marketing narrative and could enhance adoption as they move towards a Full Market Release in April 2026, addressing a critical safety and staffing issue in endovascular procedures.
At the time of this filing, MBOT was trading at $2.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $160.5M. The 52-week trading range was $1.25 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.